Patents Issued in January 30, 2024
  • Chromatography membranes, devices containing them, and methods of use thereof
    Patent number: 11884701
    Abstract: Described herein are fluid treatment devices for use in tangential flow filtration, comprising a housing unit and a composite material, wherein the composite material comprises: a support member comprising a plurality of pores extending through the support member; and a non-self-supporting macroporous cross-linked gel comprising macropores having an average size of 10 nm to 3000 nm, said macroporous gel being located in the pores of the support member. The invention also relates to a method of separating a substance from a fluid, comprising the step of placing the fluid in contact with an inventive device, thereby adsorbing or absorbing the substance to the composite material contained therein.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: January 30, 2024
    Assignee: Merck Millipore Ltd.
    Inventors: Damian Brellisford, Donna Lisa Crossley, Greg McIntosh, Robert Ruman, John Rydall, Christopher S. Shields
  • Systems and methods for process scale isolation of immunoglobulin G
    Patent number: 11884702
    Abstract: Methods are provided for isolation of immunoglobulin G (IgG) from plasma, where IgG is initially fractioned by salt precipitation, followed by successive ion exchange steps in which IgG appears in unbound, flow-through fractions of the ion exchange steps. Some embodiments employ successive anion exchange steps. Other embodiments employ an anion exchange step followed by application of flow-through of the anion exchange step to a cation exchange step, with IgG collected in flow-through fractions from the cation exchange step. IgG is collected at high yield (typically about 75% or greater) and high purity. Avoidance of binding and elution from chromatography media simplifies processing and scale up without sacrificing IgG quality or yield.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: January 30, 2024
    Assignee: Plasma Technologies, LLC
    Inventors: Eugene Zurlo, Dennis Curtin, Klaus Peter Radtke, Ryan Dorfman, Matthew Whelihan
  • Methods of processing a fluid including a recombinant therapeutic protein and use thereof
    Patent number: 11884703
    Abstract: Provided herein are methods of processing a fluid that include the use of one or both of a circuit system including a tangential flow filtration (TFF) unit and a circuit system including a tangential flow virus filtration (TFVF) unit. Also provided are integrated and continuous processes for manufacturing a therapeutic protein drug substance that include a step of processing a fluid including the recombinant therapeutic protein using any of the methods provided herein.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: January 30, 2024
    Assignee: Genzyme Corporation
    Inventors: Tarl Vetter, Michael Coolbaugh, Veena Warikoo, Konstantin Konstantinov
  • Compositions comprising HIV envelopes to induce CH235 lineage antibodies
    Patent number: 11884704
    Abstract: In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: January 30, 2024
    Assignees: DUKE UNIVERSITY, TRIAD NATIONAL SECURITY, LLC
    Inventors: Barton F. Haynes, Mattia Bonsignori, Hua-Xin Liao, Bette T. Korber, Peter T. Hraber, Kevin O. Saunders
  • Immunoglobulin binding protein, and affinity support using same
    Patent number: 11884705
    Abstract: Provided are a protein L-derived immunoglobulin binding protein having an increased antibody dissociation rate under acidic conditions, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin ? chain binding activity.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 30, 2024
    Assignees: JSR CORPORATION, JSR Life Sciences Corporation, JSR Life Sciences, LLC, JSR Micro N.V.
    Inventors: Jun-ichi Yasuoka, Kiichi Yoshimura, Tomoaki Haga
  • Immunomodulating peptide derived from concave-eared torrent frog and use thereof
    Patent number: 11884706
    Abstract: The present invention relates to an immunomodulating peptide comprising an amino acid sequence as shown in SEQ ID NO:1. The present invention also discloses use of the immunomodulating peptide in the preparation of a drug or skin care product for promoting skin wound healing. The present invention provides a new immunomodulating peptide and use thereof, and discloses the mechanism of action of the immunomodulating peptide in promoting wound healing. The immunomodulating peptide is useful as a wounding healing polypeptide template.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: January 30, 2024
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Lin Wei, Yang Yang, Wei Xu
  • Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
    Patent number: 11884707
    Abstract: The present application provides stable peptide-based IDO1 capture agents and methods of use as detection, imaging, diagnostic and therapeutic agents. The application further provides methods of manufacturing IDO1 imaging agents.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 30, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Bert Tsunyin Lai, Heather Dawn Agnew
  • Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs
    Patent number: 11884708
    Abstract: The invention concerns stapled peptide inhibitors of NEMO which inhibit the Nuclear Factor ?B (NF-?B) signaling pathway and are useful as medicine candidates, in particular as anti-inflammatory or anticancer drugs.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: January 30, 2024
    Assignee: INSTITUT PASTEUR
    Inventors: Fabrice Agou, Alix Boucharlat, Yves-Marie Coic, Françoise Baleux
  • Peptides for the treatment of resorptive bone disease
    Patent number: 11884709
    Abstract: Described are methods and associated uses for the treatment of resorptive bone disease using peptides comprising part of the C-terminal portion of soricidin. Also described are methods and associated uses for inhibiting osteoclast activity and/or bone resorption using the peptides.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: January 30, 2024
    Assignee: University of New Brunswick
    Inventors: Alli Murugesan, Anthony Reiman
  • Peptide compounds and methods of use in wound healing
    Patent number: 11884710
    Abstract: Peptide compounds and compositions containing the peptide compounds and methods for treating various infections, wounds, and skin conditions such as atopic dermatitis. Examples of wounds that may be treated include surface wounds such as lacerations, abrasions, avulsions, incisions, and amputations, pressure sores, bed sores, wounds due to peripheral vascular disease, post-surgical wounds, diabetic ulcers and wounds, burns, ocular wounds and abrasions, ocular ulcers, and treatment of inflammatory conditions such as dry eye. The peptide compounds and compositions may be used as treatments to enhance acceptance of grafts such as skin grafts and organ grafts.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: January 30, 2024
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Heloise Anne Pereira, Anne Kasus-Jacobi, Gina L. Griffith
  • Fusion proteins of GDF15 and use thereof
    Patent number: 11884711
    Abstract: The present disclosure provides fusion polypeptides comprising serum albumin binding single domain antibody and GDF15, the polypeptide complexes thereof. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: January 30, 2024
    Assignee: BEIJING QL BIOPHARMACEUTICAL CO., LTD.
    Inventors: Yuanyuan Zhang, Wei Guo, Xinyu Zhao, Haixia Zou, Yaoguang Jin, Xu Chen, Peng Zhai
  • Multi-chain chimeric polypeptides and uses thereof
    Patent number: 11884712
    Abstract: Provided herein are multi-chain chimeric polypeptides that include: (a) a first chimeric polypeptide including a first target-binding domain, a soluble tissue factor domain, and a first domain of a pair of affinity domains; and (b) a second chimeric polypeptide including a second domain of a pair of affinity domains and a second target-binding domain, where the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains. Also provided here are methods of using these multi-chain chimeric polypeptides and nucleic acids encoding these multi-chain chimeric polypeptides.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: January 30, 2024
    Assignee: HCW Biologics, Inc.
    Inventor: Hing Wong
  • Acylated glucagon analogues
    Patent number: 11884713
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • Cyclic peptide analogs of melanocortin and amanitin and methods of making such
    Patent number: 11884714
    Abstract: The invention described herein is based in part on the discovery of a protein/peptide crosslink, which introduces fluorescent properties, and which has been applied to synthesize analogues of melanocortin and amanitin as choice peptides to be explored in the context of isoindole peptides. Without limitation, it is expected that those trained in the art of peptide synthesis and stapling would appreciate the consequences of this invention such that other peptides of varied length can be similarly constrained by isoindole staples as featured herein.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: January 30, 2024
    Assignees: THE UNIVERSITY OF BRITISH COLUMBIA, PROVINCIAL HEALTH SERVICES AUTHORITY
    Inventors: David Perrin, Mihajlo Todorovic, François Bénard, Chengcheng Zhang
  • Activin receptor type IIB variants and methods of use thereof
    Patent number: 11884715
    Abstract: The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and/or pulmonary hypertension.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 30, 2024
    Assignee: Keros Therapeutics, Inc.
    Inventors: Jasbir S. Seehra, Jennifer Lachey
  • Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells
    Patent number: 11884716
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified cell, e.g., a genetically modified T cell, expressing a PLA2R-CAAR wherein the expressed CAAR comprises a PLA2R extracellular domain.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Saar Gill, Jonathan Hogan, Aimee S. Payne, Baomei Wang
  • Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
    Patent number: 11884717
    Abstract: Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: January 30, 2024
    Assignees: The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Vijay K. Kuchroo, Chao Wang, Aviv Regev, Karthik Shekhar
  • Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination
    Patent number: 11884718
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: January 30, 2024
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government Of The United States As Represented By The Secretary Of The Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson
  • Anti-IL-36 antibodies and methods of use thereof
    Patent number: 11884719
    Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 30, 2024
    Assignee: 23andMe, Inc.
    Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
  • Antibody constructs for MSLN and CD3
    Patent number: 11884720
    Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: January 30, 2024
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
    Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth Nahrwold, Doris Rau
  • Erythrocyte-binding therapeutics
    Patent number: 11884721
    Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.
    Type: Grant
    Filed: January 7, 2021
    Date of Patent: January 30, 2024
    Assignee: École Polytechnique Fédérale de Lausanne (EPFL)
    Inventors: Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
  • Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
    Patent number: 11884722
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: January 30, 2024
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
  • Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
    Patent number: 11884723
    Abstract: The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: January 30, 2024
    Assignee: OSE IMMUNOTHERAPEUTICS
    Inventors: Nicolas Poirier, Vanessa Gauttier, Caroline Mary, Sabrina Pengam, Bernard Vanhove
  • Anti-PD-L1 antibodies and uses thereof
    Patent number: 11884724
    Abstract: The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: January 30, 2024
    Assignee: Merck Patent GmbH
    Inventors: Horacio G. Nastri, Christel Iffland, Olivier Leger, Qi An, Mark Cartwright, Sean D. McKenna
  • Antibody against TIM-3 and application thereof
    Patent number: 11884725
    Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: January 30, 2024
    Assignee: Ampsource Biopharma Shanghai Inc.
    Inventors: Qiang Li, Tongtong Xue, Yuncheng Zheng, Liang Xiao, Dengnian Liu, Jianyu Sun, Jiangjiang Hu, Xinlu Ma, Kangyong Zhu, Yuanli Li
  • Dosage regimen for MAdCAM antagonists
    Patent number: 11884726
    Abstract: The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: January 30, 2024
    Assignee: Pfizer Inc.
    Inventors: Fabio Cataldi, Robert A. Clare, Gail M. Comer, Vivekananda Pradhan, Alaa Ahmad, Mina Hassan-Zahraee, Mera Krishnan Tilley, Weidong Zhang, Anindita Banerjee, Karen Michelle Page, Michael Steven Vincent, David J. Von Schack
  • Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
    Patent number: 11884727
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 30, 2024
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Reducing systemic regulatory T cell levels or activity for treatment of amyotrophic lateral sclerosis
    Patent number: 11884728
    Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 30, 2024
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
  • Anti-L1CAM antibodies and uses thereof
    Patent number: 11884729
    Abstract: The present disclosure provides antibodies that specifically bind to L1CAM and compositions comprising such antibodies. Also provided herein are methods for preventing or treating diseases or conditions which comprise a tumor using the anti-L1CAM antibodies.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: January 30, 2024
    Assignee: ApitBio, Inc
    Inventors: Hyo Jeong Hong, Heesu Chae, Jisu Hong
  • Methods of sensitizing cancer to immunotherapy
    Patent number: 11884730
    Abstract: A method of sensitizing cancer to immunotherapy in a subject in need thereof includes administering to the subject a therapeutically effective amount of a CdK5 inhibitor to suppress immune checkpoint PD-L1.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: January 30, 2024
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alex Yee-Chen Huang, Agne Petrosiute
  • Vedolizumab for the treatment of fistulizing Crohn's disease
    Patent number: 11884731
    Abstract: A method for treating a human patient suffering from fistulizing Crohn's disease, comprising administering to a patient suffering from fistulizing Crohn's disease, a humanized antibody having binding specificity for human ?4?7 integrin, wherein the human patient has a seton that was surgically placed prior to administration of the antibody, and wherein the dosing regimen induces fistula(e) healing.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: January 30, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Karen L. Lasch
  • Proteins binding HER2, NKG2D and CD16
    Patent number: 11884732
    Abstract: Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 30, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz
  • Antibody variable domains targeting the NKG2D receptor
    Patent number: 11884733
    Abstract: Antibody heavy chain variable domains that can be paired with antibody light chain variable domains to form an antigen-binding site targeting the NKG2D receptor on natural killer cells are described. Proteins comprising an NKG2D antigen-binding site, pharmaceutical compositions and therapeutic methods thereof, including for the treatment of cancer, are also described.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 30, 2024
    Assignee: Dragonfly Therapeutics, Inc.
    Inventors: Gregory P. Chang, Ann F. Cheung, Asya Grinberg, William Haney, Bradley M. Lunde, Bianka Prinz
  • Anti-MET antibodies and methods of use thereof
    Patent number: 11884734
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: January 30, 2024
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Yan Yang, Sreekala Mandiyan, Brett Robinson, Lida Kimmel, Yaron Hadari, Timothy David Jones, Francis Joseph Carr, Robert George Edward Holgate, Richard Weldon
  • Agonistic anti-IL-2R antibodies and methods of use
    Patent number: 11884735
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)
    Patent number: 11884736
    Abstract: The present disclosure relates to antibodies or antigen-binding fragments thereof that bind specifically to the glucagon-like peptide 1 receptor (GLP1R) protein, and methods of use thereof. In various embodiments, the antibodies or antigen-binding fragments thereof are fully human antibodies that bind to GLP1R. In some embodiments, the antibodies or antigen-binding fragments thereof are useful for attenuating GLP1R activity, thus providing a means of treating, preventing, or alleviating a disease, disorder or condition associated with GLP1R in humans. In some embodiments, the antibodies or antigen-binding fragments thereof elevate glucose levels when administered to a subject and thereby treat hypoglycemia, such as post-bariatric hypoglycemia (PBH), by attenuating insulin secretion from pancreatic beta cells and decreasing insulin expression.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: January 30, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Haruka Okamoto, Jee H. Kim
  • Treatment of autoimmune disorders with CD154 antibodies
    Patent number: 11884737
    Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: January 30, 2024
    Assignees: UCB BIOPHARMA SRL, BIOGEN MA INC.
    Inventors: Ruth Oliver, Miren Zamacona
  • Methods and compositions for activation of T cells using nanoparticles conjugated with multiple ligands for binding receptors on T cells
    Patent number: 11884738
    Abstract: The present invention provides methods and compositions comprising a particle comprising at least two different targeting agents that each bind a different protein receptor on a T cell surface.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: January 30, 2024
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Andrew Wang, Yu Mi
  • Anti-CD20 glycoantibodies and uses thereof
    Patent number: 11884739
    Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: January 30, 2024
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Ming-Hung Tsai
  • Anti-CD20 antibody compositions
    Patent number: 11884740
    Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: January 30, 2024
    Assignees: TG Therapeutics, Inc., Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: George Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
  • Method for improving thermal stability of antibody and method for producing modified antibody
    Patent number: 11884741
    Abstract: Disclosed is a method for producing a modified antibody, comprising: in a heavy chain of the antibody, changing at least one amino acid residue selected from the group consisting of 8th to 11th amino acid residues based on Kabat method to a cysteine residue, and changing at least one amino acid residue selected from the group consisting of 109th and 110th amino acid residues based on IMGT method to a cysteine residue; and recovering the modified antibody.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: January 30, 2024
    Assignee: SYSMEX CORPORATION
    Inventors: Tomofumi Nakada, Nobuyuki Ide
  • Methods for treating conditions associated with MASP-2 dependent complement activation
    Patent number: 11884742
    Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: January 30, 2024
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Hans-Wilhelm Schwaeble, Clark E. Tedford, James B. Parent, Thomas Dudler, Gregory A. Demopulos
  • Preparation and application of an intact recombinant antibody specific to clothianidin based on the identified variable region sequence
    Patent number: 11884743
    Abstract: A variable region sequence of a specific antibody against clothianidin is provided. A gene encoding a heavy chain variable region of the antibody has an amino acid sequence shown in SEQ ID NO: 2. An intact recombinant antibody against clothianidin is provided. The intact recombinant antibody includes a heavy chain constant region, a heavy chain variable region, a light chain constant region and a light chain variable region, wherein a gene encoding the heavy chain variable region has an amino acid sequence shown in SEQ ID NO: 2. An immunostrip containing the antibody for rapid detection of clothianidin residue is also provided. The sequence genes obtained are linked to an expression vector containing a heavy chain constant region gene and a light chain constant region gene, respectively, and an intact recombinant antibody is expressed and obtained by using mammalian cells with a double-plasmid system.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: January 30, 2024
    Assignee: Zhejiang University
    Inventors: Yirong Guo, Yunyun Chang, Rubing Zou, Ying Zhao, Shasha Jiao, Guonian Zhu
  • Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
    Patent number: 11884744
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: January 30, 2024
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Method of removing lipopeptides from solutions and changing their structure
    Patent number: 11884745
    Abstract: The present invention is a method for removing lipopeptides from solutions and changing their structure from cyclic to linear. The lipopeptide capture and sequestration takes place from solutions containing water through sorption. In the case of cyclic lipopeptides, in which the peptide ring is closed by a lactone bond, sorption is additionally associated with hydrolysis reactions occurring on the surface of active carbon, leading to linearization as a result of breaking the lactone bond.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: January 30, 2024
    Assignee: INVENTIONBIO SP. Z O. O.
    Inventors: Hanna Faltynowicz, Marek Kulazynski, Marcin Lukaszewicz
  • Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
    Patent number: 11884746
    Abstract: The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: January 30, 2024
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Stephen James Moore, Margaret Thy Luu Nguyen, Daniel Robert Hostetter, Olga Vasiljeva
  • Compstatin analogs with increased solubility and improved pharmacokinetic properties
    Patent number: 11884747
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus and/or C-terminus contains an added component that improves (1) the peptide's solubility at physiological pH; (2) the peptide's plasma half-life; (3) the peptide's intraocular retention; and/or (4) the peptide's binding affinity to C3 or its fragments as compared to an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: John D. Lambris
  • Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
    Patent number: 11884748
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: January 30, 2024
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Compositions and methods for treating endometriosis
    Patent number: 11884749
    Abstract: Provided herein are peptides that bind ?-catenin, and compositions comprising said peptides. Peptides binding ?-catenin prevent translocation to the nucleus and modulate the canonical Wnt pathway. Also provided herein are methods of using said peptides and compositions in the treatment of tissue-infiltrating conditions including endometriosis.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: January 30, 2024
    Assignee: EndoMet Biosciences, Inc.
    Inventors: Tanya Petrossian, Stephen Fiacco, Tristin Rose, Amanda Hardy, Keerthi Boddupally, Matthew Willmore
  • Cationic cell penetrating peptides and the use thereof
    Patent number: 11884750
    Abstract: A cell penetrating peptide (CPP) according to the present invention is a novel cationic cell penetrating peptide that can effectively transport a biologically active molecule by passing through a cell membrane even when a biologically active molecule is bound thereto, and compared with conventional CPPs, it has excellent cell permeability enabling the transport of a biologically active molecule into cells, and the delivered biologically active molecule may effectively maintain its activity in cells. Accordingly, the CPP of the present invention may be very useful in various fields including cosmetics, diagnostics, drug delivery systems, recombinant protein vaccines, DNA/RNA therapeutics, and gene and protein therapy.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: January 30, 2024
    Assignee: CELLTROY CO., LTD.
    Inventors: Chang-Kyu Oh, Jae-Ho Lee, Soon-Ik Park, Jeong-Ho Park, Won-Jin Park, Yun-Chu Cho